Responsible Business And Impact Report

Overview

The report highlights Gilead's 2024 advances in access to medicines and scientific innovation, including its work to expand access to lenacapavir and other therapies. It reports a global workforce of 17,648 employees and emphasizes inclusion, including women comprising 33% of the Board of Directors. The report also details carbon, water, waste and packaging targets, with its Scope 1, 2 and 3 GHG reduction targets validated by SBTi.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2024
Period: Ends 31 December 2024
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level
SBTi status
CDP score

Materiality

Assessment
Basis

Assurance

Scope
Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services